



BSW Formulary Updates and Recent Decisions – April 2025

New additions to BSWformulary and Change in Traffic Light Status (TLS)

- [Accu-check device and test strips in gestational diabetes](#) – added with **AMBER** TL, information added to formulary entry and aligns formulary to current practice.
- [Cequa® ciclosporin eye drop](#) – added with **AMBER** TL as a cheaper alternative to Ikervis eye drops. Ophthalmology consultants to switch appropriate patients.
- [Desmopressin sublingual tablets](#) – **new indication** added with **AMBER** TL as a formulary formulation for patients who after a trial of standard tablets, are found to not absorb them properly (as assessed by an endocrinologist). Wording added to formulary entry.
- [Moxifloxacin eye drops](#) – added with a **RED** TL for off-label use for treatment of corneal ulcers in adults.
- [Vedolizumab for IO colitis that is refractory to infliximab](#) – added with **RED** TL as a second line option for 3 doses. Local guidelines to follow.

New and Updated Prescribing Guidelines and Shared Care Agreements

- **UPDATED** [Testosterone in Women](#) – minor update to adjust the ranges for ‘free androgen index’.

Minor amendments to Netformulary

- Discontinued drugs removed from formulary, no major impact
- Esmya moved to non-formulary as discontinued, no prescribing in primary care so no follow up required
- ADHD links updated to LDAN directorate information which shows approved providers
- HCRG have taken over the Specialist Addiction Services contract in BaNES from Turning Point, information in section on formulary website updated to reflect this
- Donepezil changed to amber TL for all localities following publication of the new dementia LES
- Freestyle Libre 3+ has replaced Freestyle Libre 3, Freestyle 2 and 3 will be discontinued, 2+ and 3+ will replace them
- Cinacalcet wording in entry amended for the SCA that has been agreed with minor amendment made following feedback from SFT consultant

What the BSW ICB formulary team are currently working on

- Relugolix guidelines for use in endometriosis
- ADHD guidance on combination treatment
- Updating the APC Terms of Reference
- Updating the dronedarone SCA
- Vitamin D guidance update
- Amiodarone SCA being considered

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net